Second-Line Docetaxel plus Cisplatin for Advanced Gastric Cancer Showing Resistance to S-1

作者：Takagawa R^*; Kunisaki C; Makino H; Nagano Y; Fujii S; Kimura J; Kosaka T; Ono H A; Akiyama H; Endo I

来源：Journal of Chemotherapy, 2011, 23(1): 44-48.

• Gastric cancer
• second line chemotherapy
• S-1
• docetaxel
• cisplatin

The purpose of this study was to clarify the efficacy and safety of docetaxel and cisplatin as second-line treatment for patients with S-1 refractory advanced gastric cancer. Between 1999 and 2006, 32 patients received docetaxel (60 mg/m(2)) and cisplatin (60 mg/m(2)) (DP regimen) on day 1 every 3 weeks. This regimen was repeated at least three times at 3-week intervals until disease progression or unacceptable toxicity was detected. The overall response rate was 21.9%. Seven patients showed partial response, 17 showed stable disease and 8 showed disease progression. The median survival time was 12.3 months after the start of the first-line treatment. The median survival time and time to progression following the DP regimen was 7.8 months and 4.0 months, respectively. The major adverse effects were leukopenia and neutropnea. Non-hematological toxicities were generally mild to moderate and controllable. This study showed satisfactory therapeutic outcomes for patients with gastric cancer refractory to S-1 chemotherapy.

• 出版日期2011-2